GlaxoSmithKline (GSK) is to transition its fleet in North America to 100% electric vehicles (EVs) by 2030.

It is part of the pharmaceutical company’s commitment to the EV100 initiative, a global initiative bringing together companies committed to switching their own and contracted fleets to EVs and installing charging infrastructure for employees and customers over the next decade.

GSK is partnering with ARI and Enel X Way for the deployment of EVs and the installation of more than 100 charging stations.

Read the whole article by the Future Net Zero here.